Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Ultragenyx Pharmaceutical with an Overweight rating and $114 price target. Ultragenyx is a commercial-stage biopharmaceutical company that develops and markets treatments for rare diseases across its multiple platforms, the analyst tells investors in a research note. The firm sees a "great entry point" with the stock down 42% over the last year. At current share levels, Ultragenyx isn’t receiving adequate credit for its commercial portfolio, which includes four therapies in five indications with Crysvita representing one of the most successful rare disease launches, the analyst tells investors in a research note. With that said, Cantor remains most excited about the company’s clinical pipeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx management to meet with Jefferies
- Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
- Ultragenyx reports inducement grant under Nasdaq listing rule
- Ultragenyx price target lowered to $130 from $135 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue